Where can I read NTRA's latest 10-K?

NTRA's latest annual report, a 10-K, was filed on Feb 27, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.

When did NTRA last file an 8-K?

On Aug 6, 2026 it furnished a press release headed “Natera Reports Second Quarter 2026 Financial Results”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 6, 2026.

Are NTRA insiders buying or selling?

Over the last 13 months insiders sold $311.5M in 132 sales and bought nothing on the open market; 77 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Sheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares on Oct 16, 2026 for $604K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.

How many SEC filings has NTRA made?

1,814 filings are on EDGAR under the registrant records that have been Natera Inc., going back to 2014; 1,463 of them are insider ownership forms (Forms 3, 4, 5 and 144).

NTRA

$413.50+1.87%

as of close, Oct 21, 2026

☾ AH $413.50 +1.87%

Natera Inc.Stock · HealthcareNasdaq Composite · 0.07% of ONEQRussell 1000 · 0.05% of IWBRussell 3000 · 0.05% of IWVUS Stock Market · 0.05% of VTIMSCI ACWI · 0.04% of ACWIMSCI World · 0.03% of URTH

PeersILMNMEDPAMTDGHIQV

Share this page

NTRA SEC filings (2026)

CIK 1604821 · Services-Medical Laboratories (SIC 8071) · incorporated in DE · fiscal year ends in December

1,814 filings on EDGAR since 2014 · 11 annual, 36 quarterly, 111 current · financial statements · earnings

Latest 10-K

Feb 27, 2026

fiscal year to Dec 31, 2025

Latest 10-Q

Aug 7, 2026

quarter to Jun 30, 2026

Latest 8-K

Aug 6, 2026

Natera Reports Second Quarter 2026 Financial Results

Last earnings release

Aug 6, 2026

−$0.47 vs −$0.47 · ▲ 21.4%

Filings on file

1,814

since 2014, 1,463 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

October 2026

September 2026

August 2026

July 2026

Jul 29Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 1,863 shares for $465K at $249.38 under a 10b5-1 plan
Jul 28Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 3,580 shares for $910K at $254.07 under a 10b5-1 plan
Jul 28Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 2,419 shares for $614K at $253.77–$254.33 under a 10b5-1 plan
Jul 28Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 1,204 shares for $306K at $254.07 under a 10b5-1 plan
Jul 28Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,003 shares for $255K at $254.07 under a 10b5-1 plan
Jul 28Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 931 shares for $237K at $254.07 under a 10b5-1 plan
Jul 28Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 191 shares for $49K at $254.07 under a 10b5-1 plan
Jul 27Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 2,190 shares for $570K at $260.49 under a 10b5-1 plan
Jul 27Insider saleRabinowitz Matthew (EXECUTIVE CHAIRMAN · Director) sold 1,718 shares for $448K at $260.49 under a 10b5-1 plan
Jul 27Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 1,010 shares for $263K at $260.49 under a 10b5-1 plan
Jul 27Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 884 shares for $230K at $260.49 under a 10b5-1 plan
Jul 27Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 782 shares for $204K at $260.49 under a 10b5-1 plan
Jul 27Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 782 shares for $204K at $260.49 under a 10b5-1 plan
Jul 27Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 288 shares for $75K at $260.49 under a 10b5-1 plan
Jul 15Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares for $411K at $273.01–$276.38 under a 10b5-1 plan
Jul 15Insider saleChapman Rowan E (Director) sold 135 shares for $37K at $274.82 under a 10b5-1 plan
Jul 13Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 3,150 shares for $837K at $262.72–$268.39 under a 10b5-1 plan
Jul 6Insider saleRabinowitz Matthew (EXECUTIVE CHAIRMAN · Director) sold 1,000 shares for $280K at $280.00 under a 10b5-1 plan
Jul 68-K8-K · Directors or officers; compensation
Jul 1Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 16,800 shares for $4.6M at $266.79–$278.77 under a 10b5-1 plan
Jul 1Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares for $819K at $267.19–$274.06 under a 10b5-1 plan

June 2026

Jun 24Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 33,600 shares for $8.5M at $250.25–$253.39 under a 10b5-1 plan
Jun 24Insider saleROSENMAN HERM (Director) sold 16,530 shares for $4.1M at $250.00 under a 10b5-1 plan
Jun 17Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares for $330K at $218.14–$222.14 under a 10b5-1 plan
Jun 16Insider saleChapman Rowan E (Director) sold 2,964 shares for $643K at $216.78 under a 10b5-1 plan
Jun 168-K8-K · Directors or officers; compensation
Jun 168-K8-K · Directors or officers; compensation; Shareholder vote results
Jun 15Insider saleRabinowitz Matthew (EXECUTIVE CHAIRMAN · Director) sold 50,000 shares for $10.7M at $209.83–$218.72 under a 10b5-1 plan
Jun 15Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 3,150 shares for $665K at $210.29–$213.54 under a 10b5-1 plan
Jun 12Insider saleRabinowitz Matthew (EXECUTIVE CHAIRMAN · Director) sold 50,000 shares for $10.7M at $209.50–$219.36 under a 10b5-1 plan
Jun 5Insider saleMarcus Gail Boxer (Director) sold 11,000 shares for $2.4M at $216.06–$218.82
Jun 58-K8-K · Directors or officers; compensation
Jun 4Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 41,124 shares for $9.1M at $212.42–$226.97 under a 10b5-1 plan
Jun 1Insider saleBOTHA ROELOF (Director) sold 78,000 shares for $17.2M at $218.69–$223.83
Jun 1Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares for $655K at $217.52–$220.67 under a 10b5-1 plan

May 2026

April 2026

Apr 29Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 3,071 shares for $603K at $196.22–$196.99 under a 10b5-1 plan
Apr 29Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 3,070 shares for $595K at $190.12–$197.26 under a 10b5-1 plan
Apr 27Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 5,838 shares for $1.2M at $203.75–$204.39 under a 10b5-1 plan
Apr 27Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 2,182 shares for $445K at $203.75–$204.39 under a 10b5-1 plan
Apr 27Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 1,993 shares for $407K at $203.75–$204.39 under a 10b5-1 plan
Apr 27Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,861 shares for $380K at $203.75–$204.39 under a 10b5-1 plan
Apr 27Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,688 shares for $345K at $203.75–$204.39 under a 10b5-1 plan
Apr 27Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 473 shares for $96K at $203.75–$204.39 under a 10b5-1 plan
Apr 23ProxyProxy · Annual report to shareholders
Apr 23ProxyProxy · Additional proxy materials
Apr 23ProxyProxy · Proxy statement
Apr 17Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares for $299K at $199.59–$199.66 under a 10b5-1 plan
Apr 1Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 8,400 shares for $1.7M at $200.79–$205.00 under a 10b5-1 plan
Apr 1Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares for $607K at $201.32–$203.31 under a 10b5-1 plan
Apr 18-K8-K · Directors or officers; compensation

March 2026

February 2026

January 2026

Jan 29Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 1,867 shares for $430K at $229.94–$230.92 under a 10b5-1 plan
Jan 28Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 3,648 shares for $867K at $237.66 under a 10b5-1 plan
Jan 28Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 2,413 shares for $573K at $237.44–$237.66 under a 10b5-1 plan
Jan 28Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 1,200 shares for $285K at $237.66 under a 10b5-1 plan
Jan 28Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,000 shares for $238K at $237.66 under a 10b5-1 plan
Jan 28Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 928 shares for $221K at $237.66 under a 10b5-1 plan
Jan 28Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 191 shares for $45K at $237.66 under a 10b5-1 plan
Jan 27Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 2,322 shares for $559K at $240.53 under a 10b5-1 plan
Jan 27Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 1,013 shares for $244K at $240.53 under a 10b5-1 plan
Jan 27Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 886 shares for $213K at $240.53 under a 10b5-1 plan
Jan 27Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 784 shares for $189K at $240.53 under a 10b5-1 plan
Jan 27Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 784 shares for $189K at $240.53 under a 10b5-1 plan
Jan 27Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 291 shares for $70K at $240.53 under a 10b5-1 plan
Jan 23Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares for $366K at $242.23–$245.62 under a 10b5-1 plan
Jan 21Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 37,175 shares for $9.0M at $235.00–$242.67 under a 10b5-1 plan
Jan 21Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 3,163 shares for $742K at $234.12–$235.82 under a 10b5-1 plan
Jan 21Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 1,590 shares for $374K at $235.00 under a 10b5-1 plan
Jan 21Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 438 shares for $103K at $235.00 under a 10b5-1 plan
Jan 21Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 339 shares for $80K at $235.00 under a 10b5-1 plan
Jan 21Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 293 shares for $69K at $235.00 under a 10b5-1 plan
Jan 20Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 71,932 shares for $16.9M at $234.74 under a 10b5-1 plan
Jan 20Insider saleBrophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 23,948 shares for $5.6M at $234.74 under a 10b5-1 plan
Jan 20Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 23,205 shares for $5.4M at $234.74 under a 10b5-1 plan
Jan 20Insider saleRABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 19,234 shares for $4.5M at $234.74 under a 10b5-1 plan
Jan 20Insider saleFesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 17,806 shares for $4.2M at $234.74 under a 10b5-1 plan
Jan 20Insider saleSheena Jonathan (Director · CO-FOUNDER) sold 2,981 shares for $700K at $234.74 under a 10b5-1 plan
Jan 128-K8-K · Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera GrowthResults of operations
Jan 2Insider saleChapman Steven Leonard (CEO AND PRESIDENT · Director) sold 3,848 shares for $881K at $228.64–$229.67 under a 10b5-1 plan
Jan 2Insider saleMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 2,951 shares for $676K at $228.33–$229.43 under a 10b5-1 plan

December 2025

Dec 58-K8-K · Natera Acquires Foresight DiagnosticsUnregistered sale of equity; Other events

November 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $311.5M in 132 sales and bought nothing on the open market; 77 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Oct 16, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $604K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$398.95–$409.36	$604K	25,005	Form 4
Oct 15, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $20.1M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$388.32–$408.24	$20.1M	2,119,394	Form 4
Oct 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $1.2M · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$411.62–$415.07	$1.2M	106,914	Form 4
Oct 1, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $526K · 1,273 sh · 10b5-1	Sold· 10b5-1 plan	1,273	$413.31	$526K	96,926	Form 4
Sep 23, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $7.0M · 18,064 sh · 10b5-1	Sold· 10b5-1 plan	18,064	$385.10–$390.53	$7.0M	18,000	Form 4
Sep 16, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $1.1M · 3,150 sh · 10b5-1	Sold· 10b5-1 plan	3,150	$348.03–$356.87	$1.1M	221,314	Form 4
Sep 15, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $18.1M · 52,000 sh · 10b5-1	Sold· 10b5-1 plan	52,000	$339.24–$351.25	$18.1M	2,125,394	Form 4
Sep 15, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $2.1M · 6,000 sh · 10b5-1	Sold· 10b5-1 plan	6,000	$350.07	$2.1M	224,464	Form 4
Sep 14, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $16.7M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$328.09–$342.51	$16.7M	2,175,394	Form 4
Sep 11, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $16.4M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$325.01–$329.62	$16.4M	2,225,394	Form 4
Sep 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $5.0M · 15,160 sh · 10b5-1	Sold· 10b5-1 plan	15,160	$326.89	$5.0M	110,859	Form 4
Sep 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $962K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$319.76–$321.91	$962K	126,019	Form 4
Sep 1, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $545K · 1,698 sh · 10b5-1	Sold· 10b5-1 plan	1,698	$320.99	$545K	98,199	Form 4
Aug 10, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $2.1M · 6,517 sh · 10b5-1	Sold· 10b5-1 plan	6,517	$321.53	$2.1M	197,257	Form 4
Aug 10, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $2.0M · 6,000 sh · 10b5-1	Sold· 10b5-1 plan	6,000	$325.32	$2.0M	230,464	Form 4
Aug 7, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $2.9M · 9,150 sh · 10b5-1	Sold· 10b5-1 plan	9,150	$308.40–$320.90	$2.9M	236,464	Form 4
Aug 7, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $642K · 2,000 sh · 10b5-1	Sold· 10b5-1 plan	2,000	$320.90	$642K	2,000	Form 4
Aug 4, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $131K · 478 sh · 10b5-1	Sold· 10b5-1 plan	478	$274.22	$131K	51,637	Form 4
Aug 3, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $906K · 3,410 sh · 10b5-1	Sold· 10b5-1 plan	3,410	$259.98–$268.70	$906K	129,019	Form 4
Aug 3, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $819K · 3,076 sh · 10b5-1	Sold· 10b5-1 plan	3,076	$259.98–$268.22	$819K	99,897	Form 4
Aug 3, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $196K · 731 sh · 10b5-1	Sold· 10b5-1 plan	731	$267.99	$196K	2,275,394	Form 4
Aug 3, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $90K · 334 sh · 10b5-1	Sold· 10b5-1 plan	334	$267.99	$90K	170,073	Form 4
Aug 3, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $85K · 317 sh · 10b5-1	Sold· 10b5-1 plan	317	$267.99	$85K	52,115	Form 4
Aug 3, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $79K · 295 sh · 10b5-1	Sold· 10b5-1 plan	295	$267.99	$79K	183,774	Form 4
Aug 3, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $29K · 109 sh · 10b5-1	Sold· 10b5-1 plan	109	$267.99	$29K	245,614	Form 4
Jul 29, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $465K · 1,863 sh · 10b5-1	Sold· 10b5-1 plan	1,863	$249.38	$465K	52,432	Form 4
Jul 28, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $910K · 3,580 sh · 10b5-1	Sold· 10b5-1 plan	3,580	$254.07	$910K	102,973	Form 4
Jul 28, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $614K · 2,419 sh · 10b5-1	Sold· 10b5-1 plan	2,419	$253.77–$254.33	$614K	54,295	Form 4
Jul 28, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $306K · 1,204 sh · 10b5-1	Sold· 10b5-1 plan	1,204	$254.07	$306K	132,429	Form 4
Jul 28, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $255K · 1,003 sh · 10b5-1	Sold· 10b5-1 plan	1,003	$254.07	$255K	170,407	Form 4
Jul 28, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $237K · 931 sh · 10b5-1	Sold· 10b5-1 plan	931	$254.07	$237K	184,069	Form 4
Jul 28, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $49K · 191 sh · 10b5-1	Sold· 10b5-1 plan	191	$254.07	$49K	245,723	Form 4
Jul 27, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $570K · 2,190 sh · 10b5-1	Sold· 10b5-1 plan	2,190	$260.49	$570K	106,553	Form 4
Jul 27, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $448K · 1,718 sh · 10b5-1	Sold· 10b5-1 plan	1,718	$260.49	$448K	2,276,125	Form 4
Jul 27, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $263K · 1,010 sh · 10b5-1	Sold· 10b5-1 plan	1,010	$260.49	$263K	133,633	Form 4
Jul 27, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $230K · 884 sh · 10b5-1	Sold· 10b5-1 plan	884	$260.49	$230K	171,410	Form 4
Jul 27, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $204K · 782 sh · 10b5-1	Sold· 10b5-1 plan	782	$260.49	$204K	56,714	Form 4
Jul 27, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $204K · 782 sh · 10b5-1	Sold· 10b5-1 plan	782	$260.49	$204K	185,000	Form 4
Jul 27, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $75K · 288 sh · 10b5-1	Sold· 10b5-1 plan	288	$260.49	$75K	245,914	Form 4
Jul 15, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $411K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$273.01–$276.38	$411K	36,064	Form 4
Jul 15, 2026Form 4	Chapman Rowan EDirectorSold · $37K · 135 sh · 10b5-1	Sold· 10b5-1 plan	135	$274.82	$37K	4,663	Form 4
Jul 13, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $837K · 3,150 sh · 10b5-1	Sold· 10b5-1 plan	3,150	$262.72–$268.39	$837K	246,202	Form 4
Jul 6, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $280K · 1,000 sh · 10b5-1	Sold· 10b5-1 plan	1,000	$280.00	$280K	4,000	Form 4
Jul 1, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $4.6M · 16,800 sh · 10b5-1	Sold· 10b5-1 plan	16,800	$266.79–$278.77	$4.6M	172,294	Form 4
Jul 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $819K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$267.19–$274.06	$819K	134,643	Form 4
Jun 24, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $8.5M · 33,600 sh · 10b5-1	Sold· 10b5-1 plan	33,600	$250.25–$253.39	$8.5M	189,094	Form 4
Jun 24, 2026Form 4	ROSENMAN HERMDirectorSold · $4.1M · 16,530 sh · 10b5-1	Sold· 10b5-1 plan	16,530	$250.00	$4.1M	4,250	Form 4
Jun 17, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $330K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$218.14–$222.14	$330K	37,564	Form 4
Jun 16, 2026Form 4	Chapman Rowan EDirectorSold · $643K · 2,964 sh · 10b5-1	Sold· 10b5-1 plan	2,964	$216.78	$643K	3,124	Form 4
Jun 15, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $10.7M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$209.83–$218.72	$10.7M	2,277,843	Form 4
Jun 15, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $665K · 3,150 sh · 10b5-1	Sold· 10b5-1 plan	3,150	$210.29–$213.54	$665K	249,352	Form 4
Jun 12, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $10.7M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$209.50–$219.36	$10.7M	2,327,843	Form 4
Jun 5, 2026Form 4	Marcus Gail BoxerDirectorSold · $2.4M · 11,000 sh	Sold	11,000	$216.06–$218.82	$2.4M	6,183	Form 4
Jun 4, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $9.1M · 41,124 sh · 10b5-1	Sold· 10b5-1 plan	41,124	$212.42–$226.97	$9.1M	108,743	Form 4
Jun 1, 2026Form 4	BOTHA ROELOFDirectorSold · $17.2M · 78,000 sh	Sold	78,000	$218.69–$223.83	$17.2M	1,076,198	Form 4
Jun 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $655K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$217.52–$220.67	$655K	137,643	Form 4
May 26, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $335K · 1,652 sh · 10b5-1	Sold· 10b5-1 plan	1,652	$202.84	$335K	140,643	Form 4
May 26, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $292K · 1,438 sh · 10b5-1	Sold· 10b5-1 plan	1,438	$202.84	$292K	185,782	Form 4
May 13, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $302K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$199.43–$203.30	$302K	39,064	Form 4
May 8, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $657K · 3,150 sh · 10b5-1	Sold· 10b5-1 plan	3,150	$205.43–$210.35	$657K	252,502	Form 4
May 5, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $1.5M · 6,986 sh · 10b5-1	Sold· 10b5-1 plan	6,986	$205.22–$241.39	$1.5M	2,377,843	Form 4
May 4, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $149K · 722 sh · 10b5-1	Sold· 10b5-1 plan	722	$206.16	$149K	2,382,440	Form 4
May 4, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $101K · 482 sh · 10b5-1	Sold· 10b5-1 plan	482	$210.49	$101K	57,496	Form 4
May 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $694K · 3,405 sh · 10b5-1	Sold· 10b5-1 plan	3,405	$200.95–$206.93	$694K	142,295	Form 4
May 1, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $186K · 902 sh · 10b5-1	Sold· 10b5-1 plan	902	$206.16	$186K	149,867	Form 4
May 1, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $68K · 330 sh · 10b5-1	Sold· 10b5-1 plan	330	$206.16	$68K	222,694	Form 4
May 1, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $65K · 313 sh · 10b5-1	Sold· 10b5-1 plan	313	$206.16	$65K	57,978	Form 4
May 1, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $60K · 291 sh · 10b5-1	Sold· 10b5-1 plan	291	$206.16	$60K	187,220	Form 4
May 1, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $22K · 107 sh · 10b5-1	Sold· 10b5-1 plan	107	$206.16	$22K	255,652	Form 4
Apr 29, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $603K · 3,071 sh · 10b5-1	Sold· 10b5-1 plan	3,071	$196.22–$196.99	$603K	255,711	Form 4
Apr 29, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $595K · 3,070 sh · 10b5-1	Sold· 10b5-1 plan	3,070	$190.12–$197.26	$595K	58,291	Form 4
Apr 27, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $1.2M · 5,838 sh · 10b5-1	Sold· 10b5-1 plan	5,838	$203.75–$204.39	$1.2M	150,769	Form 4
Apr 27, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $445K · 2,182 sh · 10b5-1	Sold· 10b5-1 plan	2,182	$203.75–$204.39	$445K	145,700	Form 4
Apr 27, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $407K · 1,993 sh · 10b5-1	Sold· 10b5-1 plan	1,993	$203.75–$204.39	$407K	61,361	Form 4
Apr 27, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $380K · 1,861 sh · 10b5-1	Sold· 10b5-1 plan	1,861	$203.75–$204.39	$380K	223,024	Form 4
Apr 27, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $345K · 1,688 sh · 10b5-1	Sold· 10b5-1 plan	1,688	$203.75–$204.39	$345K	187,511	Form 4
Apr 27, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $96K · 473 sh · 10b5-1	Sold· 10b5-1 plan	473	$203.75–$204.39	$96K	258,782	Form 4
Apr 17, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $299K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$199.59–$199.66	$299K	40,564	Form 4
Apr 1, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $1.7M · 8,400 sh · 10b5-1	Sold· 10b5-1 plan	8,400	$200.79–$205.00	$1.7M	224,885	Form 4
Apr 1, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $607K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$201.32–$203.31	$607K	147,882	Form 4
Mar 20, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $300K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$198.49–$200.97	$300K	42,064	Form 4
Mar 18, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $608K · 3,070 sh · 10b5-1	Sold· 10b5-1 plan	3,070	$196.27–$198.65	$608K	259,255	Form 4
Mar 16, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $9.8M · 50,000 sh · 10b5-1	Sold· 10b5-1 plan	50,000	$190.07–$198.02	$9.8M	2,310,772	Form 4
Mar 13, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $14.2M · 75,000 sh · 10b5-1	Sold· 10b5-1 plan	75,000	$187.63–$191.22	$14.2M	2,310,772	Form 4
Mar 13, 2026Form 4	Chapman Rowan EDirectorSold · $23K · 122 sh · 10b5-1	Sold· 10b5-1 plan	122	$191.38	$23K	5,752	Form 4
Mar 12, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorSold · $14.3M · 75,000 sh · 10b5-1	Sold· 10b5-1 plan	75,000	$186.75–$195.32	$14.3M	2,310,772	Form 4
Mar 10, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $1.1M · 5,623 sh · 10b5-1	Sold· 10b5-1 plan	5,623	$204.13	$1.1M	156,607	Form 4
Mar 10, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $356K · 1,745 sh · 10b5-1	Sold· 10b5-1 plan	1,745	$204.13	$356K	233,285	Form 4
Mar 10, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $187K · 915 sh · 10b5-1	Sold· 10b5-1 plan	915	$204.13	$187K	150,882	Form 4
Mar 10, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $160K · 785 sh · 10b5-1	Sold· 10b5-1 plan	785	$204.13	$160K	63,354	Form 4
Mar 10, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $144K · 707 sh · 10b5-1	Sold· 10b5-1 plan	707	$204.13	$144K	189,199	Form 4
Mar 10, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $26K · 127 sh · 10b5-1	Sold· 10b5-1 plan	127	$204.13	$26K	262,325	Form 4
Mar 6, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $1.6M · 8,398 sh · 10b5-1	Sold· 10b5-1 plan	8,398	$193.73–$198.04	$1.6M	233,285	Form 4
Mar 2, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $790K · 3,950 sh · 10b5-1	Sold· 10b5-1 plan	3,950	$199.17–$201.18	$790K	156,607	Form 4
Mar 2, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $615K · 3,070 sh · 10b5-1	Sold· 10b5-1 plan	3,070	$198.50–$202.85	$615K	262,194	Form 4
Mar 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $600K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$198.83–$200.97	$600K	150,023	Form 4
Feb 3, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $1.6M · 6,939 sh · 10b5-1	Sold· 10b5-1 plan	6,939	$225.25–$230.77	$1.6M	52,120	Form 4
Feb 3, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $1.1M · 4,725 sh · 10b5-1	Sold· 10b5-1 plan	4,725	$230.77	$1.1M	123,156	Form 4
Feb 3, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $830K · 3,594 sh · 10b5-1	Sold· 10b5-1 plan	3,594	$230.77–$231.14	$830K	178,081	Form 4
Feb 3, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $378K · 1,639 sh · 10b5-1	Sold· 10b5-1 plan	1,639	$230.77	$378K	137,847	Form 4
Feb 3, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $308K · 1,334 sh · 10b5-1	Sold· 10b5-1 plan	1,334	$230.77	$308K	223,813	Form 4
Feb 3, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $100K · 435 sh · 10b5-1	Sold· 10b5-1 plan	435	$230.77	$100K	263,161	Form 4
Feb 2, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $19.7M · 85,299 sh · 10b5-1	Sold· 10b5-1 plan	85,299	$229.08–$234.00	$19.7M	127,881	Form 4
Feb 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $694K · 3,000 sh · 10b5-1	Sold· 10b5-1 plan	3,000	$228.50–$234.00	$694K	139,486	Form 4
Jan 29, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $430K · 1,867 sh · 10b5-1	Sold· 10b5-1 plan	1,867	$229.94–$230.92	$430K	59,059	Form 4
Jan 28, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $867K · 3,648 sh · 10b5-1	Sold· 10b5-1 plan	3,648	$237.66	$867K	213,180	Form 4
Jan 28, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $573K · 2,413 sh · 10b5-1	Sold· 10b5-1 plan	2,413	$237.44–$237.66	$573K	60,926	Form 4
Jan 28, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $285K · 1,200 sh · 10b5-1	Sold· 10b5-1 plan	1,200	$237.66	$285K	142,486	Form 4
Jan 28, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $238K · 1,000 sh · 10b5-1	Sold· 10b5-1 plan	1,000	$237.66	$238K	225,147	Form 4
Jan 28, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $221K · 928 sh · 10b5-1	Sold· 10b5-1 plan	928	$237.66	$221K	175,540	Form 4
Jan 28, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $45K · 191 sh · 10b5-1	Sold· 10b5-1 plan	191	$237.66	$45K	263,596	Form 4
Jan 27, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $559K · 2,322 sh · 10b5-1	Sold· 10b5-1 plan	2,322	$240.53	$559K	216,828	Form 4
Jan 27, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $244K · 1,013 sh · 10b5-1	Sold· 10b5-1 plan	1,013	$240.53	$244K	143,686	Form 4
Jan 27, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $213K · 886 sh · 10b5-1	Sold· 10b5-1 plan	886	$240.53	$213K	226,147	Form 4
Jan 27, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $189K · 784 sh · 10b5-1	Sold· 10b5-1 plan	784	$240.53	$189K	63,339	Form 4
Jan 27, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $189K · 784 sh · 10b5-1	Sold· 10b5-1 plan	784	$240.53	$189K	176,468	Form 4
Jan 27, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $70K · 291 sh · 10b5-1	Sold· 10b5-1 plan	291	$240.53	$70K	263,787	Form 4
Jan 23, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $366K · 1,500 sh · 10b5-1	Sold· 10b5-1 plan	1,500	$242.23–$245.62	$366K	43,564	Form 4
Jan 21, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $9.0M · 37,175 sh · 10b5-1	Sold· 10b5-1 plan	37,175	$235.00–$242.67	$9.0M	64,123	Form 4
Jan 21, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $742K · 3,163 sh · 10b5-1	Sold· 10b5-1 plan	3,163	$234.12–$235.82	$742K	264,078	Form 4
Jan 21, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $374K · 1,590 sh · 10b5-1	Sold· 10b5-1 plan	1,590	$235.00	$374K	219,150	Form 4
Jan 21, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $103K · 438 sh · 10b5-1	Sold· 10b5-1 plan	438	$235.00	$103K	227,033	Form 4
Jan 21, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $80K · 339 sh · 10b5-1	Sold· 10b5-1 plan	339	$235.00	$80K	177,252	Form 4
Jan 21, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $69K · 293 sh · 10b5-1	Sold· 10b5-1 plan	293	$235.00	$69K	144,699	Form 4
Jan 20, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $16.9M · 71,932 sh · 10b5-1	Sold· 10b5-1 plan	71,932	$234.74	$16.9M	217,354	Form 4
Jan 20, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERSold · $5.6M · 23,948 sh · 10b5-1	Sold· 10b5-1 plan	23,948	$234.74	$5.6M	99,776	Form 4
Jan 20, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $5.4M · 23,205 sh · 10b5-1	Sold· 10b5-1 plan	23,205	$234.74	$5.4M	144,992	Form 4
Jan 20, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSold · $4.5M · 19,234 sh · 10b5-1	Sold· 10b5-1 plan	19,234	$234.74	$4.5M	226,615	Form 4
Jan 20, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERSold · $4.2M · 17,806 sh · 10b5-1	Sold· 10b5-1 plan	17,806	$234.74	$4.2M	177,591	Form 4
Jan 20, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERSold · $700K · 2,981 sh · 10b5-1	Sold· 10b5-1 plan	2,981	$234.74	$700K	267,050	Form 4
Jan 2, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorSold · $881K · 3,848 sh · 10b5-1	Sold· 10b5-1 plan	3,848	$228.64–$229.67	$881K	136,568	Form 4
Jan 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSold · $676K · 2,951 sh · 10b5-1	Sold· 10b5-1 plan	2,951	$228.33–$229.43	$676K	123,499	Form 4

Awards, exercises, withholding and plan purchases · 77 transactions

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Oct 15, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $521K · 50,000 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	50,000	$10.41	$521K	2,169,394	Form 4
Oct 15, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 50,000 sh · 10b5-1	Exercise or conversion· Stock Option (right to buy)· 10b5-1 plan	50,000	$0.00	$0	0	Form 4
Oct 7, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorGift · $0 · 6,000 sh	Gift	6,000	$0.00	$0	2,119,394	Form 4
Sep 16, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSGift · $0 · 945 sh	Gift	945	$0.00	$0	109,914	Form 4
Aug 6, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAward · $0 · 20,000 sh · 10b5-1	Award· 10b5-1 plan	20,000	$0.00	$0	203,774	Form 4
Jun 26, 2026Form 4	Lynch Thomas J. Jr.DirectorAward · — · 1,905 sh	Award	1,905	—	—	1,905	Form 4
Jun 26, 2026Form 4	BOTHA ROELOFDirectorAward · — · 1,691 sh	Award	1,691	—	—	4,585	Form 4
Jun 26, 2026Form 4	ROSENMAN HERMDirectorAward · — · 1,677 sh	Award	1,677	—	—	5,927	Form 4
Jun 26, 2026Form 4	Chapman Rowan EDirectorAward · — · 1,674 sh	Award	1,674	—	—	4,798	Form 4
Jun 26, 2026Form 4	Marcus Gail BoxerDirectorAward · — · 1,669 sh	Award	1,669	—	—	7,852	Form 4
Jun 26, 2026Form 4	Baynes Roy D.DirectorAward · — · 1,646 sh	Award	1,646	—	—	20,158	Form 4
Jun 26, 2026Form 4	Bertagnolli MonicaDirectorAward · — · 1,646 sh	Award	1,646	—	—	7,020	Form 4
Jun 26, 2026Form 4	Rubin Eric HDirectorAward · — · 75 sh	Award	75	—	—	2,204	Form 4
Jun 5, 2026Form 4	Marcus Gail BoxerDirectorExercise or conversion · $251K · 11,000 sh	Exercise or conversion	11,000	$22.83	$251K	17,183	Form 4
Jun 5, 2026Form 4	Marcus Gail BoxerDirectorExercise or conversion · Stock Option (right to buy) · $0 · 11,000 sh	Exercise or conversion· Stock Option (right to buy)	11,000	$0.00	$0	11,000	Form 4
May 29, 2026Form 4	Rubin Eric HDirectorAward · — · 2,124 sh	Award	2,124	—	—	2,129	Form 4
May 5, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorAward · — · 2,389 sh · 10b5-1	Award· 10b5-1 plan	2,389	—	—	2,378,791	Form 4
Apr 24, 2026Form 4	BOTHA ROELOFDirectorAward · — · 354 sh	Award	354	—	—	2,894	Form 4
Apr 24, 2026Form 4	ROSENMAN HERMDirectorAward · — · 339 sh	Award	339	—	—	20,780	Form 4
Apr 24, 2026Form 4	Chapman Rowan EDirectorAward · — · 336 sh	Award	336	—	—	6,088	Form 4
Apr 24, 2026Form 4	Marcus Gail BoxerDirectorAward · — · 330 sh	Award	330	—	—	6,183	Form 4
Apr 24, 2026Form 4	Williams Brinkley RuthDirectorAward · — · 86 sh	Award	86	—	—	5,475	Form 4
Apr 24, 2026Form 4	Baynes Roy D.DirectorAward · — · 83 sh	Award	83	—	—	18,512	Form 4
Apr 24, 2026Form 4	Bertagnolli MonicaDirectorAward · — · 83 sh	Award	83	—	—	5,374	Form 4
Apr 24, 2026Form 4	Rubin Eric HDirectorAward · — · 5 sh	Award	5	—	—	5	Form 4
Apr 6, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorTax withholding · $5.7M · 27,610 sh	Tax withholding	27,610	$204.87	$5.7M	2,383,162	Form 4
Apr 6, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $559K · 58,292 sh	Exercise or conversion	58,292	$9.59	$559K	2,410,772	Form 4
Apr 6, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 58,292 sh	Exercise or conversion· Stock Option (right to buy)	58,292	$0.00	$0	0	Form 4
Mar 31, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $400K · 41,708 sh	Exercise or conversion	41,708	$9.59	$400K	2,352,480	Form 4
Mar 31, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 41,708 sh	Exercise or conversion· Stock Option (right to buy)	41,708	$0.00	$0	58,292	Form 4
Mar 16, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $480K · 50,000 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	50,000	$9.59	$480K	2,360,772	Form 4
Mar 16, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 50,000 sh · 10b5-1	Exercise or conversion· Stock Option (right to buy)· 10b5-1 plan	50,000	$0.00	$0	100,000	Form 4
Mar 13, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $719K · 75,000 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	75,000	$9.59	$719K	2,385,772	Form 4
Mar 13, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 75,000 sh · 10b5-1	Exercise or conversion· Stock Option (right to buy)· 10b5-1 plan	75,000	$0.00	$0	150,000	Form 4
Mar 12, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · $719K · 75,000 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	75,000	$9.59	$719K	2,385,772	Form 4
Mar 12, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 75,000 sh · 10b5-1	Exercise or conversion· Stock Option (right to buy)· 10b5-1 plan	75,000	$0.00	$0	225,000	Form 4
Mar 9, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorAward · — · 5,623 sh · 10b5-1	Award· 10b5-1 plan	5,623	—	—	162,230	Form 4
Mar 9, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERAward · — · 1,968 sh · 10b5-1	Award· 10b5-1 plan	1,968	—	—	64,139	Form 4
Mar 9, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSAward · — · 1,774 sh · 10b5-1	Award· 10b5-1 plan	1,774	—	—	151,797	Form 4
Mar 9, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAward · — · 1,774 sh · 10b5-1	Award· 10b5-1 plan	1,774	—	—	189,906	Form 4
Mar 9, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERAward · — · 1,745 sh · 10b5-1	Award· 10b5-1 plan	1,745	—	—	235,030	Form 4
Mar 9, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERAward · — · 258 sh · 10b5-1	Award· 10b5-1 plan	258	—	—	262,452	Form 4
Mar 6, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERExercise or conversion · $110K · 5,598 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	5,598	$19.68	$110K	241,683	Form 4
Mar 6, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERExercise or conversion · Stock Option (Right to Buy) · $0 · 5,598 sh · 10b5-1	Exercise or conversion· Stock Option (Right to Buy)· 10b5-1 plan	5,598	$0.00	$0	0	Form 4
Mar 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSExercise or conversion · $49K · 5,125 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	5,125	$9.59	$49K	153,023	Form 4
Mar 2, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSExercise or conversion · Stock Option (right to buy) · $0 · 5,125 sh · 10b5-1	Exercise or conversion· Stock Option (right to buy)· 10b5-1 plan	5,125	$0.00	$0	0	Form 4
Feb 27, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorAward · — · 37,401 sh · 10b5-1	Award· 10b5-1 plan	37,401	—	—	160,557	Form 4
Feb 27, 2026Form 4	Rabinowitz MatthewEXECUTIVE CHAIRMAN · DirectorAward · — · 29,920 sh	Award	29,920	—	—	2,310,772	Form 4
Feb 27, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERAward · — · 12,272 sh	Award	12,272	—	—	236,085	Form 4
Feb 27, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERAward · — · 10,051 sh	Award	10,051	—	—	62,171	Form 4
Feb 27, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSAward · — · 10,051 sh · 10b5-1	Award· 10b5-1 plan	10,051	—	—	147,898	Form 4
Feb 27, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAward · — · 10,051 sh	Award	10,051	—	—	188,132	Form 4
Feb 27, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERAward · — · 2,103 sh · 10b5-1	Award· 10b5-1 plan	2,103	—	—	265,264	Form 4
Jan 30, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAward · — · 6,135 sh · 10b5-1	Award· 10b5-1 plan	6,135	—	—	181,675	Form 4
Jan 30, 2026Form 4	BOTHA ROELOFDirectorAward · — · 112 sh	Award	112	—	—	2,540	Form 4
Jan 30, 2026Form 4	ROSENMAN HERMDirectorAward · — · 99 sh	Award	99	—	—	20,441	Form 4
Jan 30, 2026Form 4	Chapman Rowan EDirectorAward · — · 97 sh	Award	97	—	—	5,874	Form 4
Jan 30, 2026Form 4	Marcus Gail BoxerDirectorAward · — · 91 sh	Award	91	—	—	5,853	Form 4
Jan 30, 2026Form 4	Williams Brinkley RuthDirectorAward · — · 73 sh	Award	73	—	—	5,389	Form 4
Jan 30, 2026Form 4	Baynes Roy D.DirectorAward · — · 70 sh	Award	70	—	—	18,429	Form 4
Jan 30, 2026Form 4	Bertagnolli MonicaDirectorAward · — · 70 sh	Award	70	—	—	5,291	Form 4
Jan 20, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorExercise or conversion · — · 3,386 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	3,386	—	—	220,740	Form 4
Jan 20, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorExercise or conversion · Restricted Stock Unit · $0 · 3,386 sh · 10b5-1	Exercise or conversion· Restricted Stock Unit· 10b5-1 plan	3,386	$0.00	$0	0	Form 4
Jan 20, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERExercise or conversion · — · 1,522 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	1,522	—	—	101,298	Form 4
Jan 20, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERExercise or conversion · Restricted Stock Unit · $0 · 1,522 sh · 10b5-1	Exercise or conversion· Restricted Stock Unit· 10b5-1 plan	1,522	$0.00	$0	0	Form 4
Jan 20, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERExercise or conversion · — · 856 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	856	—	—	227,471	Form 4
Jan 20, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERExercise or conversion · Restricted Stock Unit · $0 · 856 sh · 10b5-1	Exercise or conversion· Restricted Stock Unit· 10b5-1 plan	856	$0.00	$0	0	Form 4
Jan 20, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERExercise or conversion · — · 191 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	191	—	—	267,241	Form 4
Jan 20, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERExercise or conversion · Restricted Stock Unit · $0 · 191 sh · 10b5-1	Exercise or conversion· Restricted Stock Unit· 10b5-1 plan	191	$0.00	$0	0	Form 4
Jan 14, 2026Form 4	Chapman Steven LeonardCEO AND PRESIDENT · DirectorAward · $0 · 152,718 sh · 10b5-1	Award· 10b5-1 plan	152,718	$0.00	$0	289,286	Form 4
Jan 14, 2026Form 4	Brophy Michael BurkesCHIEF FINANCIAL OFFICERAward · $0 · 59,596 sh · 10b5-1	Award· 10b5-1 plan	59,596	$0.00	$0	123,722	Form 4
Jan 14, 2026Form 4	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSAward · $0 · 44,698 sh · 10b5-1	Award· 10b5-1 plan	44,698	$0.00	$0	168,197	Form 4
Jan 14, 2026Form 4	Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAward · $0 · 44,698 sh · 10b5-1	Award· 10b5-1 plan	44,698	$0.00	$0	195,397	Form 4
Jan 14, 2026Form 4	RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERAward · $0 · 37,248 sh · 10b5-1	Award· 10b5-1 plan	37,248	$0.00	$0	245,849	Form 4
Jan 14, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERAward · $0 · 7,450 sh · 10b5-1	Award· 10b5-1 plan	7,450	$0.00	$0	270,031	Form 4
Jan 5, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERExercise or conversion · $380K · 39,615 sh	Exercise or conversion	39,615	$9.59	$380K	262,581	Form 4
Jan 5, 2026Form 4	Sheena JonathanDirector · CO-FOUNDERExercise or conversion · Stock Option (right to buy) · $0 · 39,615 sh	Exercise or conversion· Stock Option (right to buy)	39,615	$0.00	$0	0	Form 4

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 15 filings

Filed	Form	What it is	Period
Aug 7, 202610-Q	10-Q	Quarterly report, Q2 2026 — revenue $752.8M (+38% y/y), net income −$67.0M, EPS −$0.47	Jun 30, 2026
Aug 6, 20268-K	8-K	Earnings release — EPS −$0.47 vs −$0.47 est. (+0.0%); revenue $752.8M (+38% y/y) 21.4%	Aug 6, 2026
Jul 6, 20268-K	8-K	Directors or officers; compensation	Jul 1, 2026
Jun 16, 20268-K/A	8-K/A	Directors or officers; compensation	Jun 2, 2026
Jun 16, 20268-K	8-K	Directors or officers; compensation; Shareholder vote results	Jun 11, 2026
Jun 5, 20268-K	8-K	Directors or officers; compensation	Jun 2, 2026
May 8, 202610-Q	10-Q	Quarterly report, Q1 2026 — revenue $696.6M (+39% y/y), net income −$85.1M, EPS −$0.60	Mar 31, 2026
May 7, 20268-K	8-K	Earnings release — EPS −$0.56 vs −$0.53 est. (−5.7%); revenue $696.6M (+39% y/y) 11.6%	May 7, 2026
Apr 23, 2026ARS	ARS	Annual report to shareholders	Dec 31, 2025
Apr 23, 2026DEFA14A	DEFA14A	Additional proxy materials	—
Apr 23, 2026DEF 14A	DEF 14A	Proxy statement	Jun 11, 2026
Apr 1, 20268-K	8-K	Directors or officers; compensation	Mar 26, 2026
Feb 27, 202610-K	10-K	Annual report, FY2025 — revenue $2.31B (+36% y/y), net income −$208.2M, EPS −$1.52	Dec 31, 2025
Feb 26, 20268-K	8-K	Earnings release — EPS $0.35 vs −$0.46 est. (+176.1%); revenue $665.5M (+40% y/y) 3.7%	Feb 26, 2026
Jan 12, 20268-K	8-K	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera GrowthResults of operations	Jan 11, 2026

2025 · 15 filings

Filed	Form	What it is	Period
Dec 5, 20258-K	8-K	Natera Acquires Foresight DiagnosticsUnregistered sale of equity; Other events	Dec 4, 2025
Nov 7, 202510-Q	10-Q	Quarterly report, Q3 2025 — revenue $592.2M (+35% y/y), net income −$87.5M, EPS −$0.64	Sep 30, 2025
Nov 6, 20258-K	8-K	Earnings release — EPS −$0.64 vs −$0.39 est. (−64.1%); revenue $592.2M (+35% y/y) 0.5%	Nov 6, 2025
Aug 8, 202510-Q	10-Q	Quarterly report, Q2 2025 — revenue $546.6M (+32% y/y), net income −$100.9M, EPS −$0.74	Jun 30, 2025
Aug 7, 20258-K	8-K	Earnings release — EPS −$0.74 vs −$0.60 est. (−23.3%); revenue $546.6M (+32% y/y) 7.7%	Aug 7, 2025
Jun 18, 20258-K	8-K	Directors or officers; compensation; Shareholder vote results	Jun 12, 2025
May 9, 202510-Q	10-Q	Quarterly report, Q1 2025 — revenue $501.8M (+36% y/y), net income −$66.9M, EPS −$0.50	Mar 31, 2025
May 8, 20258-K	8-K	Earnings release — EPS −$0.50 vs −$0.59 est. (+15.3%); revenue $501.8M (+36% y/y) 6.5%	May 8, 2025
Apr 24, 2025ARS	ARS	Annual report to shareholders	Dec 31, 2024
Apr 24, 2025DEFA14A	DEFA14A	Additional proxy materials	—
Apr 24, 2025DEF 14A	DEF 14A	Proxy statement	Jun 12, 2025
Mar 12, 20258-K	8-K	Directors or officers; compensation	Mar 6, 2025
Feb 28, 202510-K	10-K	Annual report, FY2024 — revenue $1.70B (+57% y/y), net income −$190.4M, EPS −$1.53	Dec 31, 2024
Feb 27, 20258-K	8-K	Earnings release — EPS −$0.41 vs −$0.42 est. (+2.4%); revenue $476.1M (+53% y/y) 0.7%	Feb 27, 2025
Jan 13, 20258-K	8-K	Results of operations	Jan 12, 2025

2024 · 17 filings

Filed	Form	What it is	Period
Dec 6, 20248-K	8-K	Directors or officers; compensation	Dec 2, 2024
Nov 12, 202410-Q	10-Q	Quarterly report, Q3 2024 — revenue $439.8M (+64% y/y), net income −$31.6M, EPS −$0.26	Sep 30, 2024
Nov 12, 20248-K	8-K	Earnings release — EPS −$0.26 vs −$0.57 est. (+54.4%); revenue $439.8M (+64% y/y) 19.1%	Nov 12, 2024
Aug 9, 202410-Q	10-Q	Quarterly report, Q2 2024 — revenue $413.4M (+58% y/y), net income −$37.5M, EPS −$0.30	Jun 30, 2024
Aug 8, 20248-K	8-K	Earnings release — EPS −$0.30 vs −$0.69 est. (+56.5%); revenue $413.4M (+58% y/y) 6.4%	Aug 8, 2024
Jul 22, 20248-K	8-K	Other events	Jul 19, 2024
Jun 18, 20248-K	8-K	Directors or officers; compensation; Shareholder vote results	Jun 12, 2024
Jun 5, 2024DEFA14A	DEFA14A	Additional proxy materials	—
May 10, 202410-Q	10-Q	Quarterly report, Q1 2024 — revenue $367.7M (+52% y/y), net income −$67.6M, EPS −$0.56	Mar 31, 2024
May 9, 20248-K	8-K	Earnings release — EPS −$0.56 vs −$0.72 est. (+22.2%); revenue $367.7M (+52% y/y) 10.2%	May 9, 2024
Apr 24, 2024ARS	ARS	Annual report to shareholders	Dec 31, 2023
Apr 24, 2024DEFA14A	DEFA14A	Additional proxy materials	—
Apr 24, 2024DEF 14A	DEF 14A	Proxy statement	Jun 12, 2024
Feb 29, 202410-K	10-K	Annual report, FY2023 — revenue $1.08B (+32% y/y), net income −$434.8M, EPS −$3.78	Dec 31, 2023
Feb 28, 20248-K	8-K	Earnings release — EPS −$0.64 vs −$0.73 est. (+12.3%); revenue $311.1M (+43% y/y) 13.0%	Feb 28, 2024
Jan 22, 20248-K	8-K	Other events	Jan 17, 2024
Jan 9, 20248-K	8-K	Results of operations	Jan 9, 2024

2023 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 9, 202310-Q	10-Q	Quarterly report, Q3 2023 — revenue $268.3M (+27% y/y), net income −$109.0M, EPS −$0.95	Sep 30, 2023
Aug 4, 202310-Q	10-Q	Quarterly report, Q2 2023 — revenue $261.4M (+32% y/y), net income −$110.8M, EPS −$0.97	Jun 30, 2023
May 10, 202310-Q	10-Q	Quarterly report, Q1 2023 — revenue $241.8M (+25% y/y), net income −$136.9M, EPS −$1.23	Mar 31, 2023
Apr 20, 2023ARS	ARS	Annual report to shareholders	Dec 31, 2022
Apr 20, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Apr 20, 2023DEF 14A	DEF 14A	Proxy statement	—
Mar 1, 202310-K	10-K	Annual report, FY2022 — revenue $820.2M (+31% y/y), net income −$547.8M, EPS −$5.57	Dec 31, 2022

9 current reports (8-K) not listed; the year is on EDGAR.

2022 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Filed	Form	What it is	Period
Nov 9, 202210-Q	10-Q	Quarterly report, Q3 2022 — revenue $210.6M (+33% y/y), net income −$121.5M, EPS −$1.25	Sep 30, 2022
Aug 5, 202210-Q	10-Q	Quarterly report, Q2 2022 — revenue $198.2M (+40% y/y), net income −$145.2M, EPS −$1.50	Jun 30, 2022
May 6, 202210-Q	10-Q	Quarterly report, Q1 2022 — revenue $194.1M (+27% y/y), net income −$138.6M, EPS −$1.45	Mar 31, 2022
Apr 13, 2022DEFA14A	DEFA14A	Additional proxy materials	—
Apr 13, 2022DEF 14A	DEF 14A	Proxy statement	May 25, 2022
Feb 25, 202210-K	10-K	Annual report, FY2021 — revenue $625.5M (+60% y/y), net income −$471.7M, EPS −$5.21	Dec 31, 2021

9 current reports (8-K) not listed; the year is on EDGAR.

2021 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Filed	Form	What it is	Period
Nov 5, 202110-Q	10-Q	Quarterly report, Q3 2021 — revenue $158.1M (+61% y/y), net income −$151.3M, EPS −$1.63	Sep 30, 2021
Aug 6, 202110-Q	10-Q	Quarterly report, Q2 2021 — revenue $142.0M (+64% y/y), net income −$116.0M, EPS −$1.32	Jun 30, 2021
May 7, 202110-Q	10-Q	Quarterly report, Q1 2021 — revenue $152.3M (+62% y/y), net income −$63.9M, EPS −$0.74	Mar 31, 2021
Apr 13, 2021DEFA14A	DEFA14A	Additional proxy materials	—
Apr 13, 2021DEF 14A	DEF 14A	Proxy statement	May 25, 2021
Feb 26, 202110-K	10-K	Annual report, FY2020 — revenue $391.0M (+29% y/y), net income −$229.7M, EPS −$2.84	Dec 31, 2020

8 current reports (8-K) not listed; the year is on EDGAR.

2020 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Filed	Form	What it is	Period
Nov 6, 202010-Q	10-Q	Quarterly report, Q3 2020 — revenue $98.1M (+26% y/y), net income −$58.3M	Sep 30, 2020
Aug 7, 202010-Q	10-Q	Quarterly report, Q2 2020 — revenue $86.5M (+16% y/y), net income −$59.6M	Jun 30, 2020
May 8, 202010-Q	10-Q	Quarterly report, Q1 2020 — revenue $94.0M (+41% y/y), net income −$35.4M	Mar 31, 2020
Apr 16, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Apr 16, 2020DEF 14A	DEF 14A	Proxy statement	May 28, 2020
Mar 2, 202010-K	10-K	Annual report, FY2019 — revenue $302.3M (+17% y/y), net income −$124.8M, EPS −$1.79	Dec 31, 2019

11 current reports (8-K) not listed; the year is on EDGAR.

2019 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 8, 201910-Q	10-Q	Quarterly report, Q3 2019 — revenue $77.9M (+19% y/y), net income −$23.1M, EPS −$0.33	Sep 30, 2019
Aug 9, 201910-Q	10-Q	Quarterly report, Q2 2019 — revenue $74.4M (+18% y/y), net income −$32.4M, EPS −$0.48	Jun 30, 2019
May 10, 201910-Q	10-Q	Quarterly report, Q1 2019 — revenue $66.8M (+7% y/y), net income −$34.1M, EPS −$0.54	Mar 31, 2019
Apr 4, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2019DEF 14A	DEF 14A	Proxy statement	May 16, 2019
Mar 15, 201910-K	10-K	Annual report, FY2018 — revenue $257.7M (+23% y/y), net income −$128.2M, EPS −$2.22	Dec 31, 2018
Feb 6, 201910-Q/A	10-Q/A	Quarterly report, amended	Mar 31, 2018

15 current reports (8-K) not listed; the year is on EDGAR.

2018 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 9, 201810-Q	10-Q	Quarterly report, Q3 2018 — revenue $65.3M (+17% y/y), net income −$29.6M, EPS −$0.49	Sep 30, 2018
Aug 9, 201810-Q	10-Q	Quarterly report, Q2 2018 — revenue $63.1M (+21% y/y), net income −$33.8M, EPS −$0.62	Jun 30, 2018
May 10, 201810-Q	10-Q	Quarterly report, Q1 2018 — revenue $62.3M (+26% y/y), net income −$32.9M, EPS −$0.61	Mar 31, 2018
Apr 4, 2018DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2018DEF 14A	DEF 14A	Proxy statement	May 16, 2018
Mar 22, 201810-Q/A	10-Q/A	Quarterly report, amended	Sep 30, 2017
Mar 15, 201810-K	10-K	Annual report, FY2017 — revenue $209.6M (−3% y/y), net income −$137.6M, EPS −$2.59	Dec 31, 2017

9 current reports (8-K) not listed; the year is on EDGAR.

2017 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Nov 9, 201710-Q	10-Q	Quarterly report, Q3 2017 — revenue $55.9M (+4% y/y), net income −$27.9M, EPS −$0.52	Sep 30, 2017
Aug 9, 201710-Q	10-Q	Quarterly report, Q2 2017 — revenue $52.3M (+1% y/y), net income −$29.1M, EPS −$0.55	Jun 30, 2017
May 10, 201710-Q	10-Q	Quarterly report, Q1 2017 — revenue $49.4M (−20% y/y), net income −$33.5M, EPS −$0.65	Mar 31, 2017
Apr 11, 2017DEFA14A	DEFA14A	Additional proxy materials	—
Apr 11, 2017DEF 14A	DEF 14A	Proxy statement	May 23, 2017
Mar 16, 201710-K	10-K	Annual report, FY2016 — revenue $217.1M (+14% y/y), net income −$100.3M, EPS −$1.95	Dec 31, 2016

11 current reports (8-K) not listed; the year is on EDGAR.

2016 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2015 · 8 filings — 6 × 8-K, 2 × 10-Q

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 215 filings — 137 × 4, 69 × 144, 4 × SCHEDULE 13G/A and 3 other forms

Filed	Form	What it is	Period
Oct 20, 20264	4	Insider transaction (Form 4)	Oct 16, 2026
Oct 16, 20264	4	Insider transaction (Form 4)	Oct 15, 2026
Oct 15, 2026144	144	Notice of proposed sale (Form 144)	—
Oct 9, 20264	4	Insider transaction (Form 4)	Oct 7, 2026
Oct 2, 20264	4	Insider transaction (Form 4)	Oct 1, 2026
Oct 2, 20264	4	Insider transaction (Form 4)	Oct 1, 2026
Oct 1, 2026144	144	Notice of proposed sale (Form 144)	—
Oct 1, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 25, 20264	4	Insider transaction (Form 4)	Sep 23, 2026
Sep 23, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 18, 20264	4	Insider transaction (Form 4)	Sep 16, 2026
Sep 17, 20264	4	Insider transaction (Form 4)	Sep 15, 2026
Sep 16, 20264	4	Insider transaction (Form 4)	Sep 14, 2026
Sep 15, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 11, 20264	4	Insider transaction (Form 4)	Sep 11, 2026
Sep 11, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 3, 20264	4	Insider transaction (Form 4)	Sep 1, 2026
Sep 3, 20264	4	Insider transaction (Form 4)	Sep 1, 2026
Sep 2, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 1, 2026144	144	Notice of proposed sale (Form 144)	—
Sep 1, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 28, 20264	4	Insider transaction (Form 4)	Aug 6, 2026
Aug 14, 20264	4	Insider transaction (Form 4)	Aug 10, 2026
Aug 14, 2026SCHEDULE 13G/A	SCHEDULE 13G/A	Other filings	—
Aug 7, 20264	4	Insider transaction (Form 4)	Aug 7, 2026

The newest 25 of 215 shown; the full year is on EDGAR.

2025 · 255 filings — 176 × 4, 66 × 144, 4 × SCHEDULE 13G/A and 6 other forms

Filed	Form	What it is	Period
Dec 22, 20254	4	Insider transaction (Form 4)	Dec 19, 2025
Dec 19, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 17, 20254	4	Insider transaction (Form 4)	Dec 15, 2025
Dec 17, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 16, 20254	4	Insider transaction (Form 4)	Dec 12, 2025
Dec 16, 20254	4	Insider transaction (Form 4)	Oct 31, 2025
Dec 12, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 12, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 11, 20254	4	Insider transaction (Form 4)	Dec 9, 2025
Dec 10, 2025S-3ASR	S-3ASR	Automatic shelf registration	—
Dec 10, 2025RW	RW	Other filings	—
Dec 9, 20254	4	Insider transaction (Form 4)	Dec 5, 2025
Dec 8, 20254	4	Insider transaction (Form 4)	Dec 4, 2025
Dec 5, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 5, 2025S-8	S-8	Employee stock plan registration	—
Dec 5, 2025S-3	S-3	Shelf registration	—
Dec 3, 20254	4	Insider transaction (Form 4)	Dec 1, 2025
Dec 3, 20254	4	Insider transaction (Form 4)	Dec 1, 2025
Dec 1, 2025144	144	Notice of proposed sale (Form 144)	—
Dec 1, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 26, 20254	4	Insider transaction (Form 4)	Nov 24, 2025
Nov 24, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 21, 20254	4	Insider transaction (Form 4)	Nov 20, 2025
Nov 21, 20254	4	Insider transaction (Form 4)	Nov 19, 2025
Nov 20, 2025144	144	Notice of proposed sale (Form 144)	—

The newest 25 of 255 shown; the full year is on EDGAR.

2024 · 219 filings — 155 × 4, 52 × 144, 7 × SC 13G/A and 3 other forms

Filed	Form	What it is	Period
Dec 26, 20244	4	Insider transaction (Form 4)	Dec 20, 2024
Dec 26, 20244	4	Insider transaction (Form 4)	Dec 20, 2024
Dec 23, 20244	4	Insider transaction (Form 4)	Dec 19, 2024
Dec 20, 20244	4	Insider transaction (Form 4)	Dec 18, 2024
Dec 18, 2024144	144	Notice of proposed sale (Form 144)	—
Dec 13, 20244	4	Insider transaction (Form 4)	Dec 13, 2024
Dec 13, 2024144	144	Notice of proposed sale (Form 144)	—
Dec 11, 20244	4	Insider transaction (Form 4)	Dec 10, 2024
Dec 11, 20244	4	Insider transaction (Form 4)	Dec 9, 2024
Dec 10, 2024144	144	Notice of proposed sale (Form 144)	—
Dec 10, 2024144	144	Notice of proposed sale (Form 144)	—
Dec 9, 20244	4	Insider transaction (Form 4)	Dec 5, 2024
Dec 4, 20244	4	Insider transaction (Form 4)	Dec 2, 2024
Dec 2, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 27, 20244	4	Insider transaction (Form 4)	Nov 25, 2024
Nov 26, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 25, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 21, 20244	4	Insider transaction (Form 4)	Nov 19, 2024
Nov 19, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 15, 20244	4	Insider transaction (Form 4)	Nov 15, 2024
Nov 15, 20244	4	Insider transaction (Form 4)	Nov 15, 2024
Nov 15, 20244	4	Insider transaction (Form 4)	Nov 13, 2024
Nov 15, 20244	4	Insider transaction (Form 4)	Nov 14, 2024
Nov 15, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 15, 2024144	144	Notice of proposed sale (Form 144)	—

The newest 25 of 219 shown; the full year is on EDGAR.

2023 · 142 filings — 112 × 4, 20 × 144, 4 × SC 13G/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2022 · 149 filings — 132 × 4, 7 × 4/A, 3 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2021 · 166 filings — 149 × 4, 3 × CORRESP, 3 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2020 · 130 filings — 112 × 4, 6 × SC 13G/A, 2 × 4/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2019 · 120 filings — 86 × 4, 10 × 4/A, 5 × SC 13G/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2018 · 68 filings — 56 × 4, 4 × SC 13G/A, 2 × 424B5 and 5 other forms

Counted, not listed; the year is on EDGAR.

2017 · 41 filings — 29 × 4, 3 × 3, 3 × SC 13G/A and 4 other forms

Counted, not listed; the year is on EDGAR.

2016 · 65 filings — 50 × 4, 5 × SC 13G, 3 × UPLOAD and 6 other forms

Counted, not listed; the year is on EDGAR.

2015 · 51 filings — 12 × 4, 11 × 3, 7 × CORRESP and 13 other forms

Counted, not listed; the year is on EDGAR.

2014 · 8 filings — 3 × DRS/A, 2 × DRSLTR, 2 × UPLOAD and 1 other form

Counted, not listed; the year is on EDGAR.

About this data#

Natera Inc. (NTRA) has 1,814 filings on EDGAR going back to 2014: 11 annual reports, 36 quarterly reports and 111 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 27, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 6, 2026, furnished a press release headed “Natera Reports Second Quarter 2026 Financial Results”. Over the last 13 months insiders sold $311.5M in 132 sales and bought nothing on the open market; 77 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Natera Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read NTRA's latest 10-K?: NTRA's latest annual report, a 10-K, was filed on Feb 27, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did NTRA last file an 8-K?: On Aug 6, 2026 it furnished a press release headed “Natera Reports Second Quarter 2026 Financial Results”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 6, 2026.
Are NTRA insiders buying or selling?: Over the last 13 months insiders sold $311.5M in 132 sales and bought nothing on the open market; 77 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Sheena Jonathan (Director · CO-FOUNDER) sold 1,500 shares on Oct 16, 2026 for $604K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has NTRA made?: 1,814 filings are on EDGAR under the registrant records that have been Natera Inc., going back to 2014; 1,463 of them are insider ownership forms (Forms 3, 4, 5 and 144).